Drug Approval | April 01, 2025
Morepen secures Loratadine approval for export to China
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
This program, titled "Food Supplementation and Capacity Building Support for Improved Nutrition in Malinao, Aklan," aligns with the country’s national health
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Nanomi's pioneering approach in drug delivery has set new benchmarks in the industry, and this award serves as a motivation to continue its mission to revolutionize healthcare
Over the last two years, Lupin has showcased exceptional improvement in its EcoVadis scoring
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Overall investment in the US facility is estimated around US$50 million
Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals
Yearbook members are selected basis their S&P Global 2024 Corporate Sustainability Assessment score
Subscribe To Our Newsletter & Stay Updated
